Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

Cobenfy In Alzheimer’s Psychosis Among Next Readouts

 
• By Mandy Jackson
  
BMS shares fell 5.8% on the company's disclosure of plans to review in-progress trials (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business